Nucleome Therapeutics Ltd. has nominated NTP-464 as its first preclinical development candidate and is advancing the program toward IND-enabling studies. The first-in-class monoclonal antibody agonist for inflammation resolution has broad applicability across major chronic inflammatory diseases.
Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic kidney disease, myelofibrosis or advanced solid tumors characterized by elevated pro-inflammatory cytokines where the availability for iron for erythropoiesis is limited due to increased hepcidin levels.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
NLRP3 inflammasome is a key component of the innate immune system. As a major mediator of inflammation, NLRP3 plays a central role in the pathogenesis of neurodegenerative and autoinflammatory conditions.
Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by chronic inflammation and structural damage to the alveoli, with irreversible declined lung function. M1 pro-inflammatory macrophages mainly participate in airway inflammation and in tissue destruction, and are involved in COPD, but the mechanisms need to be elucidated.
Toll-like receptor 3 (TLR3) has been noted to impact liver disease and promote liver inflammation. Researchers from Southern Medical University screened a natural product molecular library and found that ellipticine exerted moderate TLR3 inhibitory effects, with an IC50 value of 5.66 µM.
A healthy life for a healthy heart is a popular saying. However, even when following good habits, heart health can be already compromised from the very earliest stages of development. Maternal cells reach the embryo through the placenta contributing to its normal formation. So, just as the mother helps form a functional heart, she can also induce a condition that may not appear until adulthood.
Inmune Bio Inc. claimed a phase II win with TNF inhibitor Xpro (pegipanermin) in early Alzheimer’s disease (AD), though the study missed its primary and secondary endpoints, leading shares of the firm (NASDAQ:INMB) to close at $2.16, down $3.18, or almost 60%.
Persistent activation of the stimulator of interferon genes (STING), resulting from aberrant metabolism or mutations in STING1, can lead to inflammatory damage and autoimmune diseases. Therefore, inhibiting STING activity may offer therapeutic potential for treating these disorders.
